Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT) Journal Article
| Authors: | Rosenbluth, B. D.; Yahalom, J. |
| Article Title: | Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT) |
| Abstract: | Purpose: Although radiosensitivity of mantle cell lymphoma (MCL) has been demonstrated in vitro, radiotherapy is rarely employed in treatment of MCL. We studied clinical responses of MCL patients treated with involved-field radiation therapy (IFRT) predominantly for local control and/or palliation. Methods and Materials: A total of 21 consecutive patients (38 sites) treated with IFRT for MCL were retrospectively analyzed. Median age was 68. Seventeen patients had Stage IV/relapsed disease, 1 had Stage II, and 3 had Stage I disease. Most patients received prior chemotherapy, with an average of two combinations per patient. Mean number of sites treated per patient was two. Mean total dose was 30 Gy. Results: Mean follow-up was 13 months. Overall local response rate was 100%. Complete response was obtained in 64% of the sites and partial response in 36%. Average time to response was 20 days. Twenty-eight sites had a response before radiation therapy was complete. Of 16 sites associated with pre-IFRT pain or discomfort, 15 exhibited post-IFRT relief. Thirteen sites (34%) exhibited local progression, with a median time to progression of 10 months, and an average response duration of 9 months. Five patients experienced Grade II radiation-related toxicity. No Grade III toxicity was reported. Twelve-month overall survival for patients receiving IFRT was 55%. Conclusions: Radiotherapy provided effective and lasting local responses in MCL patients and was associated with minimal toxicity. Radiation doses required for most lesions were relatively low and responses were noticed early in the course of treatment. Radiation therapy should be considered early in the course of relapsing, refractory, or localized MCL. © 2006 Elsevier Inc. All rights reserved. |
| Keywords: | adult; cancer survival; clinical article; controlled study; treatment response; aged; aged, 80 and over; middle aged; survival analysis; retrospective studies; unclassified drug; fludarabine; prednisone; neutropenia; cancer localization; doxorubicin; cancer combination chemotherapy; diarrhea; cancer patient; cancer radiotherapy; radiation dose; ibritumomab tiuxetan; methotrexate; rituximab; cancer staging; follow up; neoplasm staging; anorexia; cancer palliative therapy; palliative care; carboplatin; bortezomib; mantle cell lymphoma; anemia; etoposide; esophagitis; mucosa inflammation; nausea; antineoplastic combined chemotherapy protocols; radiotherapy; cyclophosphamide; vincristine; patient monitoring; radiation injury; oncology; retrospective study; ifosfamide; procarbazine; monoclonal antibody; survival time; prednisolone; mitoxantrone; data analysis; taste disorder; xerostomia; erythema; cancer relapse; radiosensitivity; pancytopenia; toxicity; bone marrow transplantation; tositumomab i 131; chlorambucil; pentostatin; lymphoma, mantle-cell; cladribine; lesion; pharyngitis; appetite disorder; application site pain; involved-field radiation therapy; involved-field radiation therapy (ifrt); mantle cell lymphoma (mcl); relapsing; monoclonal antibody c25; application site discomfort; involved field radiation therapy |
| Journal Title: | International Journal of Radiation Oncology, Biology, Physics |
| Volume: | 65 |
| Issue: | 4 |
| ISSN: | 0360-3016 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2006-07-15 |
| Start Page: | 1185 |
| End Page: | 1191 |
| Language: | English |
| DOI: | 10.1016/j.ijrobp.2006.02.011 |
| PUBMED: | 16682133 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 6" - "Export Date: 4 June 2012" - "CODEN: IOBPD" - "Source: Scopus" |
